Full-Time

Vice President

Clinical Development

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Hybrid role requiring on-site presence in Cambridge several times per week.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD, DO or equivalent ex-US medical degree with 15+ years’ experience, 10+ years clinical development experience in industry is a must.
  • Board certification/eligibility in hematology, or equivalent is a must. Transplant experience is highly desirable.
  • Must have previous patient care experience.
  • Demonstrated ability to successfully execute clinical development projects across all phases of drug discovery.
  • Proven track record of successful interactions with regulatory authorities.
  • Demonstrated ability to lead and influence experienced professionals.
  • Experience working with commercial strategies in required.
  • Ability to lead in a fast-changing environment.
  • Broad knowledge and exposure across all R&D functions.
  • Deep understanding of pre-clinical/clinical pharmaceutical development.
  • Strategic thinker with strong execution skills.
  • Effective communicator.
Responsibilities
  • Lead efforts to develop, refine a vision for the Beam hematology franchise strategy in a collaborative environment.
  • Develop and implement near- and long-term goals and objectives that are aligned with the strategic vision.
  • In line with corporate objectives, provide relevant medical counsel and scientific guidance to all teams across Beam that are involved in hematology therapeutic-related activities.
  • Work with cross-functional teams to develop integrated clinical/regulatory strategies for key initiatives to support the successful registration and commercialization of products for the hematology therapeutic area.
  • Support cross-functional hematology teams.
  • Design clinical development plans, target-product profiles and protocols that are aligned to support the integrated clinical/regulatory/commercial strategies for the therapeutic area.
  • Provide strategic and medical oversite of planned and ongoing clinical trials.
  • Ensure high quality clinical development standards with respect to clinical study design, conduct and oversight of patient safety.
  • Support the Research & Development Leadership Team as well as Business Development as it relates to hematology research and clinical development activities.
  • Attend and help prepare material for medical conferences, Regulatory Agency meetings, Advisory Boards and other relevant clinical events as required.
  • Mentor junior clinical research and development physicians and clinical scientists.

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Unlike many competitors, Beam Therapeutics emphasizes collaboration with pharmaceutical companies and research institutions, which helps them secure funding and support for their projects. The ultimate goal of Beam Therapeutics is to advance scientific research and deliver effective, long-lasting treatments for patients suffering from genetic conditions.

Company Stage

IPO

Total Funding

$215.9M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

2%

1 year growth

-2%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam Therapeutics' innovative base editing technology has the potential to revolutionize the treatment of genetic disorders, offering hope for lifelong cures.
  • The company's strong pipeline, including early-stage studies for sickle cell disease, positions it well for future growth and breakthroughs.
  • Significant investments and partnerships, like the recent $250 million deal with Eli Lilly, enhance Beam's financial stability and research capabilities.

What critics are saying

  • The recent retirement of CFO Terry-Ann Burrell and the layoff of 20% of staff could lead to operational disruptions and affect company morale.
  • Beam's focus on early-stage studies means that its treatments are still years away from commercialization, posing a risk to short-term revenue generation.

What makes Beam Therapeutics unique

  • Beam Therapeutics leverages base editing technology, which allows for precise genetic modifications, setting it apart from traditional gene-editing methods like CRISPR.
  • The company's focus on developing lifelong cures for genetic disorders, rather than temporary treatments, distinguishes it in the biotechnology sector.
  • Beam's strategic partnerships and licensing agreements, such as the $250 million deal with Eli Lilly, provide significant financial backing and collaborative opportunities.

Help us improve and share your feedback! Did you find this helpful?